Daiichi Sankyo to acquire 2% of own shares
This article was originally published in Scrip
Executive Summary
The board of Daiichi Sankyohas approved a new buyback plan under which the firm will acquire up to 15 million of its own outstanding ordinary shares for a maximum of ¥50 billion ($470.0 million) over the July-August period. The total represents around 2% of the company's outstanding shares. Takeda is planning to cancel around 2% of its shares under a similar programme, as part of efforts by major Japanese pharma firms to improve shareholder returns and to guard against any potential hostile takeover bid through the open market.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.